SOFIE Inc, a Theranostics company, has signed a global license with University Clinic Heidelberg for a class of molecular targeted diagnostics and radiotherapeutics that are aimed at identifying and breaking down cancer associated fibroblasts in tumour stroma and irradiate nearby cancer cells, it was reported on Friday.
The license includes the small molecule inhibitors of fibroblast activation-protein (FAP) inhibitors that can be named alternatively with different radioisotopes; those for diagnostic imaging to identify patients whose tumours contain fibroblast activation-protein inhibitors with high expression of fibroblast activation-protein inhibitors, and those for radiotherapeutic treatment of these patients.
More than 200 patients were imaged at the University Clinic Heidelberg, while five other academic centres in Germany investigating patients with a wide range of cancers. Moreover, a small number of patients received compassionate care therapy on an individual patient basis at Heidelberg University Hospital and were analysed in an approved retrospective observational study.
Philipp Czernin, SOFIE's chief revenue officer, led the negotiations with University Clinic Heidelberg.
Scancell initiates SCOPE trial's iSCIB1+ cohort
Bio-Thera Solutions' BAT8006 phase II Study receives US FDA IND approval
Poseida Therapeutics names new chief medical officer
Biocytogen and ABL Bio collaborate on development of new bispecific antibody-drug conjugates
BioVaxys Technology announces non-brokered private placement
Senhwa Biosciences doses first subject in phase II study of Silmitasertib
Antennova completes first dosing cohort in Phase one study of ATN-031
M8 Pharmaceuticals collaborates with SERB Pharmaceuticals
BerGenBio ASA starts Phase 2a portion of BGBC016 clinical study of bemcentinib
Phanes Therapeutics receives FDA Fast Track designation for PT886